2-[(3S)-3-methylmorpholin-4-yl]pyrimidin-5-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(3S)-3-methylmorpholin-4-yl]pyrimidin-5-amine
• 化学式: C₉H₁₄N₄O
• 分子量: 194.236
• InChiKey: SZMGFROEAHSLCR-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  64.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  三光气 、 (1R)-1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethanamine 、 2-[(3S)-3-methylmorpholin-4-yl]pyrimidin-5-amine 以 二氯甲烷 为溶剂， 以6.35 %的产率得到3-[(1R)-1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethyl]-1-{2-[(3S)-3-methylmorpholin-4-yl]pyrimidin-5-yl}urea
  参考文献：
  名称：

  [EN] UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER
  [FR] DÉRIVÉS D'URÉE POUVANT ÊTRE UTILISÉS POUR TRAITER LE CANCER

  摘要：

  This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2022265993A1
• 作为产物：
  描述：

  (3S)-3-methyl-4-(5-nitropyrimidin-2-yl)morpholine 在 铁粉 、 氯化铵 作用下， 以 乙醇 为溶剂， 以65.71 %的产率得到2-[(3S)-3-methylmorpholin-4-yl]pyrimidin-5-amine
  参考文献：
  名称：

  [EN] UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER
  [FR] DÉRIVÉS D'URÉE POUVANT ÊTRE UTILISÉS POUR TRAITER LE CANCER

  摘要：

  This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2022265993A1